Log in to search using one of your social media accounts:

 

Study explains why myasthenia patients relapse after treatment
A new Yale-led study helps explain why some myasthenia gravis (MG) patients relapse after initially responding to a drug called rituximab. (Source: Yale Science and Health News)
Source: Yale Science and Health News - September 7, 2017 Category: Universities & Medical Training Source Type: news

Scientists make first crystal model of under-diagnosed autoimmune disease
(University of Southern California) Doctors are limited in how they can treat patients with myasthenia gravis, an autoimmune disease, to just treating its symptoms. The creation of a crystal model gives scientists new insight into a possible target for drug therapy development. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - June 12, 2017 Category: Biology Source Type: news

Disease Awareness Months Work, Even If You Don't Wear The Ribbon
June ​is the month for more than 10 disease-related awareness campaigns, including Myasthenia Gravis Awareness Month, National Congenital Cytomegalovirus Awareness Month and National Scleroderma Awareness Month. It also hosts a handful of awareness weeks and days, ranging from Helen Keller Deaf-Blind Awareness Week to World Sickle Cell Day. June’s awareness list is shorter than most, but every month is full of diseases and disorders to take note of. You probably haven’t heard of half of them, and you’re not alone. So what’s the point of an awareness day, week or month? To understand the chall...
Source: Healthy Living - The Huffington Post - June 2, 2017 Category: Consumer Health News Source Type: news

New York Academy of Sciences to host conference on myasthenia gravis & related disorders
(New York Academy of Sciences) From May 15th to 17th the New York Academy of Sciences in partnership with the Myasthenia Gravis Foundation of America will host the 13th International Conference on Myasthenia Gravis and Related Disorders. The conference convenes every five years and is the preeminent gathering of basic scientists and clinical researchers to discuss, disseminate, and highlight the advances and challenges of therapies for myasthenia gravis (MG) and related autoimmune diseases. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 12, 2017 Category: International Medicine & Public Health Source Type: news

Alexion submits application to Japan ’s MHLW to extend Soliris indication to treat gMG
Alexion Pharmaceuticals has submitted an application to extend the indication for Soliris (eculizumab) as a potential treatment for patients with refractory generalised myasthenia gravis (gMG). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - March 24, 2017 Category: Pharmaceuticals Source Type: news

Catalyst Pharma's Neuromuscular Drug Succeeds in Study Catalyst Pharma's Neuromuscular Drug Succeeds in Study
Catalyst Pharmaceuticals Inc said on Wednesday its experimental drug to treat patients with a severe form of myasthenia gravis (MG), a rare neuromuscular disease, met the main goals of a study.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - March 16, 2017 Category: Allergy & Immunology Tags: Neurology & Neurosurgery News Source Type: news

Catalyst Pharmaceuticals reports positive results from MuSK-MG trial of Firdapse to treat MG
Catalyst Pharmaceuticals has reported positive top-line results from the MuSK-MG clinical trial of Firdapse to treat patients with myasthenia gravis (MG). (Source: Drug Development Technology)
Source: Drug Development Technology - March 16, 2017 Category: Pharmaceuticals Source Type: news

Catalyst Pharma's neuromuscular drug succeeds in study
(Reuters) - Catalyst Pharmaceuticals Inc said on Wednesday its experimental drug to treat patients with a severe form of myasthenia gravis (MG), a rare neuromuscular disease, met the main goals of a study. (Source: Reuters: Health)
Source: Reuters: Health - March 15, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

What is in the Differential Diagnosis of Fatigue?
Discussion Fatigue is a subjective feeling of decreased energy, tiredness or feeling of exhaustion. Lethargy is often used synonymously, but lethargy is a state of being drowsiness or sleepy, and implies mental status changes. Both can cause the person to be apathetic or less active. Fatigue is a common state that almost everyone experiences multiple times in his or her lifetime. For most people it is a relatively acute or short-term chronic problem, often with a relatively easily identifiable problem cause, such as inadequate sleep, acute illness, or overexertion. For some, it can be less readily identifiable such as dep...
Source: PediatricEducation.org - January 23, 2017 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

Myasthenia gravis and its aeromedical implications - Jagathesan T, O'Brien MD.
BACKGROUND: Myasthenia gravis is an autoimmune condition where antibodies form against the acetylcholine receptors at the neuromuscular junction, eventually causing damage to the motor end plate. The clinical features include muscle fatigability as well as... (Source: SafetyLit)
Source: SafetyLit - January 14, 2017 Category: Global & Universal Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news

Your NEJM Group Today: Myasthenia Gravis, Top Gastroenterology Stories of 2016, Washington State Family Med Opportunities (FREE)
By the Editors NEJM Group offers so many valuable resources for clinicians. Here's what we chose for you today:NEJM Clinical Practice Center: Review article: Myasthenia … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - January 3, 2017 Category: Primary Care Source Type: news

Catalyst begins enrolment for second Phase III LMS-003 trial of Firdapse to treat LEMS
US-based biopharmaceutical company Catalyst has begun enrolment for its second Phase III LMS-003 clinical trial of Firdapse to treat Lambert-Eaton myasthenic syndrome (LEMS). (Source: Drug Development Technology)
Source: Drug Development Technology - December 19, 2016 Category: Pharmaceuticals Source Type: news

Rituximab Effective, Durable in Refractory Myasthenia Gravis Rituximab Effective, Durable in Refractory Myasthenia Gravis
Dr Laurie Barclay discusses results from a small study and what they may mean for incorporating rituximab in the treatment of myasthenia gravis.Medscape Neurology (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - December 12, 2016 Category: Neurology Tags: Neurology & Neurosurgery Viewpoint Source Type: news

Catalyst Pharmaceuticals Provides Update on its Clinical Trial for Patients with Congenital Myasthenic Syndromes
CORAL GABLES, Fla., Dec. 08, 2016 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases,... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - December 8, 2016 Category: Drugs & Pharmacology Source Type: news

Your NEJM Group Today: Ice-Pack Test for Myasthenia Gravis, Childhood BMI & Later Psychosocial Health, Massachusetts Urgent Care Opportunities (FREE)
By the Editors NEJM Group offers so many valuable resources for practicing clinicians. Here's what we chose for you today:NEJM Clinical Practice Center: Image in Clinical Medicine: … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - November 13, 2016 Category: Primary Care Source Type: news

FDA approval brings biopharma firm one step closer to lucrative pharmaceutical submarket
Shares of Catalyst Pharmaceuticals (Nasdaq: CPRX) jumped more than 12 percent Friday following announcement of the U.S. Food and Drug Administration's stamp of approval on its latest drug. A medicine created by the Coral Gables-based company called Firdapse earned “orphan” status, a designation for drugs that safely and effectively treat or prevent rare diseases. Firdapse aims to treat a portion of the 100,000 Americans who suffer of myasthenia gravis, a degenerative neuromuscu lar disease that… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - September 2, 2016 Category: Pharmaceuticals Authors: Debora Lima Source Type: news

Surgery Effective for Muscle-Weakening Disorder
Myasthenia gravis affects 60,000 Americans, but removal of thymus gland appears to help, research shows (Source: WebMD Health)
Source: WebMD Health - August 11, 2016 Category: Consumer Health News Source Type: news

Surgery Effective Against Immune Disorder That Weakens Muscles
Myasthenia gravis affects 60,000 Americans, but removal of thymus gland appears to help, research shows Source: HealthDay Related MedlinePlus Page: Myasthenia Gravis (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - August 11, 2016 Category: Consumer Health News Source Type: news

Thymectomy Bests Medical Therapy in Myasthenia Gravis Thymectomy Bests Medical Therapy in Myasthenia Gravis
' The trial ends an 80-year controversy'about benefits of thymectomy for patients with major myasthenia gravis but no thymus tumor, experts say.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - August 11, 2016 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

NIH-funded study supports surgery as treatment for myasthenia gravis
Autoimmune disease causes muscle weakness and fatigue. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - August 11, 2016 Category: American Health Source Type: news

Surgery Effective Against Immune Disorder That Weakens Muscles
THURSDAY, Aug. 11, 2016 -- Removing the thymus gland is an effective treatment for myasthenia gravis, an autoimmune disorder that causes life-threatening muscle weakness, researchers report. Since the 1940s, doctors have been surgically removing... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 11, 2016 Category: Journals (General) Source Type: news

Thymectomy improves clinical outcomes for myasthenia gravis
Thymectomy improved 3-year clinical outcomes and proved superior to medical therapy for mild to severe nonthymomatous myasthenia gravis, according to a report published online Aug. 11 in the New... (Source: Family Practice News)
Source: Family Practice News - August 10, 2016 Category: Primary Care Source Type: news

NIH-funded study supports surgery as treatment for myasthenia gravis
In a global study of myasthenia gravis, an autoimmune disease that causes muscle weakness and fatigue, researchers found that surgical removal of an organ called the thymus reduced patients ’ weakness, and their need for immunosuppressive drugs. The study, published in the New England Journal of Medicine, was partially funded by the National Institutes of Health. (Source: NINDS Press Releases and News: National Institute of Neurological Disorders and Stroke)
Source: NINDS Press Releases and News: National Institute of Neurological Disorders and Stroke - August 10, 2016 Category: Neurology Source Type: news

New Consensus Guidance on Myasthenia Gravis New Consensus Guidance on Myasthenia Gravis
The new international expert consensus is intended to be a guide for clinicians caring for patients with myasthenia gravis worldwide. Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - July 12, 2016 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Success With Stem Cell Transplant in Myasthenia Gravis Success With Stem Cell Transplant in Myasthenia Gravis
Seven patients with severe myasthenia gravis who received autologous hematopoietic stem cell transplants have experienced long-term remission. Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - May 4, 2016 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

What it’s like to be in neurology: Shadowing Dr. Govindarajan
As a medical student, do you ever wonder what it’s like to be a neurologist? Here’s your chance to find out. Meet Raghav Govindarajan, MD, a neurologist and featured physician in AMA Wire’s® “Shadow Me” Specialty Series, which offers advice directly from physicians about life in their specialties. Read his insights to help determine whether a career in neurology might be a good fit for you. "Shadowing" Dr. Govindarajan Specialty: Neurology Practice setting: University hospital Years in practice: 2 A typical week in my practice: I am a neurologist with special...
Source: AMA Wire - April 18, 2016 Category: Journals (General) Authors: Amy Farouk Source Type: news

What it ’s like to be in neurology: Shadowing Dr. Govindarajan
As a medical student, do you ever wonder what it ’s like to be a neurologist? Here’s your chance to find out. Meet Raghav Govindarajan, MD, a neurologist and featured physician in AMA Wire ’s ® “Shadow Me” Specialty Series , which offers advice directly from physicians about life in their specialties. Read his insights to help determine whether a career in neurology might be a good fit for you. " Shadowing " Dr.  Govindarajan Specialty: Neurology Practice setting: University hospital Years in practice: 2 A typical week in my practice: I am a neurologist wit...
Source: AMA Wire - April 18, 2016 Category: Journals (General) Authors: Amy Farouk Source Type: news

Autologous haematopoietic stem cell transplantation promise for myasthenia gravis
Study findings in seven patients with severe myasthenia gravis support the use of autologous haematopoietic stem cell transplantation for achieving long-term remission. (Source: MedWire News)
Source: MedWire News - April 6, 2016 Category: Consumer Health News Tags: Neurology Source Type: news

Stem Cell Therapy May Work in Severe Myasthenia Gravis (CME/CE)
(MedPage Today) -- Small single-center study supports autologous stem cell transplant for severe myasthenia gravis (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - April 5, 2016 Category: Neurology Source Type: news

Study examines impact of 2 new antibodies in causing, treating myasthenia gravis
(Medical College of Georgia at Augusta University) A study of patients from across the nation with myasthenia gravis is helping determine the incidence of two new antibodies believed to cause the disease, and whether these patients need different treatment strategies. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 5, 2016 Category: Global & Universal Source Type: news

Catalyst Pharmaceuticals Receives "Refusal to File" Letter From the FDA on Its NDA for Firdapse
CORAL GABLES, Fla., Feb. 17, 2016 -- (Healthcare Sales & Marketing Network) -- Catalyst Pharmaceuticals, Inc. (CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, tod... Biopharmaceuticals, FDACatalyst Pharmaceuticals, Firdapse, amifampridine, Lambert Eaton Myasthenic (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 17, 2016 Category: Pharmaceuticals Source Type: news

Lambert-Eaton Syndrome: Causes, Symptoms & Treatments
Lambert-Eaton syndrome also known as, 'Lambert-Eaton myasthenic syndrome,' is a condition in which a person's immune system attacks their neuromuscular junctions, the areas where your nerves and muscles connect. Usually a person's nerve cells pass signals along to their muscles. The signals help to make your muscles move. Due to the fact that Lambert-Eaton syndrome affects the way a person's nerves and muscles communicate, moving muscles becomes difficult. (Source: Disabled World)
Source: Disabled World - December 27, 2015 Category: Disability Tags: Autoimmune Diseases Source Type: news

Catalyst Pharmaceuticals Completes NDA Submission to FDA for Firdapse for the Treatment of Lambert-Eaton Myasthenic Syndrome and Congenital Myasthenic Syndromes
CORAL GABLES, Fla., Dec. 17, 2015 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, announced... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - December 17, 2015 Category: Drugs & Pharmacology Source Type: news

ARJ Infusion Services, Lonnie Kersey Receives Prestigious Award from...
Myasthenia Gravis Association of Kansas City presented Lonnie Kersey the “Stackhouse Distinguished Service Award”. It's the organization's most prominent award of the year.(PRWeb November 12, 2015)Read the full story at http://www.prweb.com/releases/2015/11/prweb13075792.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - November 13, 2015 Category: Pharmaceuticals Source Type: news

Orphan Drug Shown Effective for LEMS WeaknessOrphan Drug Shown Effective for LEMS Weakness
The study was designed to finally earn FDA approval for 3,4 DAP, long used to treat Lambert-Eaton myasthenic syndrome on a compassionate basis. Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - October 7, 2015 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

FDA panel recommends limited use of Bayer’s Essure until more is known about safety
An FDA advisory panel yesterday recommended that the agency limit the use of Bayer‘s (ETR:BAYN) Essure female sterilization device until more is known about its safety, after thousands of women reported serious health issues they attribute to the nickel-titanium implant. Essure, the only approved permanent birth control device in the U.S., is a small metal coil that is placed in the fallopian tubes via catheter. The FDA approved the device in November 2002. In the near 13 years since then, the health regulator said it had received 5,093 complaints, including those of pain or menstrual irregularities af...
Source: Mass Device - September 25, 2015 Category: Medical Equipment Authors: Brad Perriello Tags: Food & Drug Administration (FDA) Regulatory/Compliance Women's Health Bayer HealthCare Obstetrics and Gynecology Devices Advisory Panel Source Type: news

The Emerging Role of Tacrolimus in Myasthenia GravisThe Emerging Role of Tacrolimus in Myasthenia Gravis
Is the immunosuppressive drug tacrolimus beneficial in reducing symptoms of myasthenia gravis? This review summarizes the latest evidence. Therapeutic Advances in Neurological Disorders (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 26, 2015 Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news

Pediatric Patient Loses Spontaneous Respirations
Matthew, a 6-year-old male, has been feeling increasingly short of breath throughout the course of the morning. His father also notices that over the last several days he’s been appearing increasingly tired with a cough. Matthew is watching TV on the floor in the living room when his father enters the room and finds him unresponsive and apneic. He calls 9-1-1. The Call Paramedics respond immediately, but the response is uneventful. They arrive on scene and are met outside by the patient’s father, who takes them into the house and tells them his son has been feeling ill over the past several days but wasn’...
Source: JEMS Special Topics - March 11, 2015 Category: Emergency Medicine Authors: Elizabeth K. Powell, MD Tags: Case of the Month Pediatrics Airway & Respiratory Source Type: news

Score in Development to Detect Myasthenia Gravis WorseningScore in Development to Detect Myasthenia Gravis Worsening
A scoring system can help predict the risk for conversion from ocular myasthenia gravis to generalized disease, a new study has shown. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 26, 2015 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

New Diagnostic Test Proposed for Myasthenia GravisNew Diagnostic Test Proposed for Myasthenia Gravis
Ocular vestibular-evoked myogenic potentials could be used to diagnose myasthenia gravis, researchers report. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 25, 2015 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Myasthenia Gravis Therapeutic Pipeline Drugs and Companies Review H2...
RnRMarketResearch.com adds Myasthenia Gravis Pipeline Review H2 2014 to its store. The report provides an overview of the Myasthenia Gravis therapeutic pipeline.(PRWeb December 15, 2014)Read the full story at http://www.prweb.com/releases/2014-h2-myasthenia-gravis/pipeline-review-market/prweb12395670.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - December 16, 2014 Category: Pharmaceuticals Source Type: news

High prevalence of vitamin D deficiency across the board in neuromuscular disease
More credence has been added to a growing awareness of the high prevalence of vitamin D deficiency in neuromuscular disease by newly presented research. Vitamin D supplementation has been suggested to improve function in frail elderly patients at risk for falls, as well as individuals with myasthenia gravis and Parkinson's. The impact of vitamin D deficiency and supplementation on function in other neurologic conditions has yet to be explored. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - October 31, 2014 Category: Science Source Type: news

Efficacy of potential therapy for autoimmune disorder of muscle weakness
(University of Pennsylvania School of Medicine) Researchers have made a fast-acting 'vaccine' that can reverse the course of myasthenia gravis, a non-inherited autoimmune form of muscle weakness, in an animal model of the disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 7, 2014 Category: Global & Universal Source Type: news

Amy Guy can't move facial muscles due to incurable condition that's killing her muscles
Amy Guy, 34, from Southampton, has Myasthenia gravis. The condition causes certain muscles - including those that control facial expression - to become weak. (Source: the Mail online | Health)
Source: the Mail online | Health - October 3, 2014 Category: Consumer Health News Source Type: news

Alexion receives orphan drug designation for Soliris in Europe
The European Commission has granted orphan drug designation to Alexion Pharmaceuticals’ Soliris (eculizumab), a terminal complement inhibitor, to treat patients with myasthenia gravis (MG). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - August 4, 2014 Category: Pharmaceuticals Source Type: news

European Commission Grants Orphan Drug Designation to Soliris(R) (eculizumab) for the Treatment of Patients with Myasthenia Gravis (MG)
CHESHIRE, Conn.--(Healthcare Sales & Marketing Network)--Alexion Pharmaceuticals (ALXN) today announced that the European Commission has granted orphan drug designation (ODD) to Soliris® (eculizumab) for the treatment of patients with Myasthenia Gravis... Biopharmaceuticals, RegulatoryAlexion Pharmaceuticals, Soliris, eculizumab, Myasthenia Gravis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 1, 2014 Category: Pharmaceuticals Source Type: news

Therapeutic Options for Juvenile Myasthenia GravisTherapeutic Options for Juvenile Myasthenia Gravis
The outcomes with plasmapheresis and IVIG as maintenance therapies are compared in a 33-year retrospective analysis. Medscape Neurology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 2, 2014 Category: Consumer Health News Tags: Neurology & Neurosurgery Viewpoint Source Type: news

Mitochondrial Mutation Linked to Congenital Myasthenic Syndrome
Although significant progress has been made over the last 25 years to identify genetic abnormalities associated with congenital myasthenic syndromes (CMS), many patients remain genetically undiagnosed. A report now identifies a gene defect in mitochondria, specifically the citrate carrier SLC25A1, that may underlie deficits in neuromuscular transmission seen in two siblings. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - June 20, 2014 Category: Science Source Type: news